Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FDA warns Amgen over cancer drug promotional video

28 October 2026 · By · Wire by Fusion42

Published

28 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 28 October 2026 · Fusion42 review

The US FDA issued a warning to Amgen for a promotional video of its colorectal cancer drug Vectibix that misleadingly highlighted benefits without adequately disclosing serious safety risks and patient limitations. The FDA demanded corrective actions and cessation of the misleading video use.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

FDA's crackdown on misleading cancer drug advertising is a clear sign you must ensure your promotional materials fully disclose safety risks or face enforcement. This regulatory scrutiny tightens market access and amplifies the need to align marketing with compliance now.

◆ Coverage

1 source · 28 Oct 2026

◆ Related on Wire

◆ Topics

BiotechFDAdrug-safetypromotional-compliancecancer-drugspharma-regulation